Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces
Tóm tắt
Hepatitis C virus (HCV) imposes a considerable disease burden in China, with at least 10 million people chronically infected. Little is known about the financial impact of the HCV epidemic, nor about the extent to which various forms of insurance are providing HCV patients with financial protection. A cross-sectional multi-site study was conducted to acquire data that will aid policy-makers and other stakeholders in developing effective strategies to address this situation. At 29 hospitals across China, inpatients and outpatients with chronic HCV were surveyed about their insurance coverage and medical costs. Percentages, means and medians were calculated, and differences in continuous variables among multiple groups were analyzed using the Kruskal-Wallis test or Wilcoxon two-sample test. Many inpatients (N = 593) and outpatients (N = 523) reported being covered by one of three major types of government health insurance, but 13 % of inpatients and 43 % of outpatients reported having no insurance. Among inpatients, the total median cost per hospitalization per patient was 8212 Renminbi (RMB). The category of expenditure with the highest median cost per hospitalization was Western medicine, followed by lab tests and Chinese medicine. The median cost per hospitalization was far higher for patients who had hepatocellular carcinoma than for those with less severe forms of liver disease. Outpatient antiviral therapy costs ranged from a median of 377 RMB for ribavirin to a median of 37,400 RMB for pegylated interferon-alpha for up to one year of treatment. For uninsured chronic HCV patients in China, inpatient and outpatient costs may be financially devastating. Research is needed on how different approaches to financing HCV treatment and care might improve health outcomes as well as achieve cost savings by enabling more people to be cured of HCV.
Tài liệu tham khảo
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61–80. doi:10.1111/j.1478-3231.2011.02540.x.
Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099–108. doi:10.1002/hep.27406.
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45–57. doi:10.1016/j.jhep.2014.07.027.
Duan Z, Jia JD, Hou J, Lou L, Tobias H, Xu XY, et al. Current challenges and the management of chronic hepatitis C in mainland China. J Clin Gastroenterol. 2014;48(8):679–86. doi:10.1097/mcg.0000000000000109.
The Chinese medical association of liver branch idapeboCma. Guidelines on the management of hepatitis C. Chin J Hepatol. 2004;12(1674–7380):194–8.
World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2014.
Hepatitis C guidance. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–54. doi:10.1002/hep.27950.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74. doi:10.1002/hep.22759.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. doi:10.1002/hep.24199.
Wang Z, Zhang Y, Xiong F, Li H, Ding Y, Gao Y, et al. Association between medical insurance type and survival in patients undergoing peritoneal dialysis. BMC Nephrol. 2015;16:33. doi:10.1186/s12882-015-0023-7.
Zhang L, Liu N. Health reform and out-of-pocket payments: lessons from China. Health Policy Plan. 2014;29(2):217–26. doi:10.1093/heapol/czt006.
Long Q, Xu L, Bekedam H, Tang S. Changes in health expenditures in China in 2000s: has the health system reform improved affordability. Int J Equity Health. 2013;12:40. doi:10.1186/1475-9276-12-40.
China NBoSotPsPo. Chinese economy continues to maintain steady and rapid development in 2011. 2011. http://www.stats.gov.cn/tjsj/zxfb/201201/t20120117_12777.html. Accessed January 17, 2012.
Younossi ZM, Otgonsuren M, Henry L, Arsalla Z, Stepnaova M, Mishra A, et al. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. J Viral Hepat. 2015;22(2):137–45. doi:10.1111/jvh.12262.
Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014;28(5):243–50.
Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56(5):1651–60. doi:10.1002/hep.25842.
Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011;56(10):3024–31. doi:10.1007/s10620-011-1802-z.
Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, et al. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. J Med Econ. 2014;17(12):862–71. doi:10.3111/13696998.2014.964720.
Federico CA, Hsu PC, Krajden M, Yoshida EM, Bremner KE, Weiss AA, et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int. 2012;32(5):815–25. doi:10.1111/j.1478-3231.2011.02722.x.